3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors

Journal of Molecular Graphics and Modelling

Volumn 26, Issue 7, 2008, Pages 1169-1178

  Awale, Mahendra ^a   Mohan, C Gopi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

CoMFA; EGFR; Human epidermal growth factor receptor; Receptor tyrosine kinase

Indexed keywords

CRYSTAL STRUCTURE; MATHEMATICAL MODELS; ONCOLOGY; PROTEINS; SUBSTITUTION REACTIONS;

COMFA; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR; RECEPTOR TYROSINE KINASE;

ENZYME INHIBITION;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PYRROLOTRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG STRUCTURE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL SIGNIFICANCE; SUBSTITUTION REACTION;

EID: 40649119472     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2007.10.008     Document Type: Article

References (15)

1. S. Menard P. Casalini M. Campiglio S.M. Pupa E. Tagliabue Role of HER2/neu in tumor progression and therapy Cell Mol. Life Sci. 61 2004 2965 2978
2. A. Jimeno M. Hidalgo Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors Biochim. Biophys. Acta (BBA)-Rev. Cancer 1766 2006 217 229
3. R. Worthylake L.K. Opresko H.S. Wiley ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J. Biol. Chem. 274 1999 8865 8874
4. M. Van de Vijver Genetic alterations in intraductal and invasive breast cancer Eur. J. Cancer 37 2001 12 112
5. Y. Yarden M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
6. J.T. Hunt T. Mitt R. Borzilleri J. Gullo-Brown J. Fargnoli B. Fink W.C. Han S. Mortillo G. Vite B. Wautlet Discovery of the pyrrolo [2,1-f][1,2, 4] triazine nucleus as a new kinase inhibitor template J. Med. Chem. 47 2004 4054 4059
7. W.-m. Shi Q. Shen W. Kong B.-x. Ye QSAR analysis of tyrosine kinase inhibitor using modified ant colony optimization and multiple linear regression Eur. J. Med. Chem. 42 2007 81 86
8. S. Kamath J.K. Buolamwini Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors J. Med. Chem. 46 2003 4657 4668
9. H. Mastalerz M. Chang P. Chen P. Dextraze B.E. Fink A. Gavai B. Goyal W.C. Han W. Johnson D. Langley F.Y. Lee P. Marathe A. Mathur S. Oppenheimer E. Ruediger J. Tarrant J.S. Tokarski G.D. Vite D.M. Vyas H. Wong T.W. Wong H. Zhang G. Zhang New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 17 2007 2036 2042
10. R.D. Cramer III D.E. Patterson J.D. Bunce Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 110 1988 5959 5967
11. SYBYL7.1, Tripos Inc., St. Louis, MO 63144, USA.
12. S. Wold A. Johansson M. Cochi PLS-partial least square projection to latent structures H. Kubinyi 3D-QSAR in Drug Design: Theory, Methods and Applications 1993 ESCOM Leiden 523 550
13. R.D. Cramer III J.D. Bunce D.E. Paterson I.E. Frank Cross-validation, boot-strapping and partial least squares compared with multiple regression in conventional QSAR studies Quant. Struct. -Act. Relat. 7 1988 18 25
14. H. Mastalerz M. Chang A. Gavai W. Johnson D. Langley F.Y. Lee P. Marathe A. Mathur S. Oppenheimer J. Tarrant Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 17 2007 2828 2833
15. J. Singh E.M. Dobrusin D.W. Fry T. Haske A. Whitty D.J. McNamara Structure-based design of a potent, selective and irreversible inhibitors of the catalytic domain of erbB receptor subfamily of protein tyrosine kinases J. Med. Chem. 40 1997 1130 1135